<DOC>
	<DOCNO>NCT01605006</DOCNO>
	<brief_summary>This post-approval study follow 60 participant ALS , document chronic hypoventilation , bilateral phrenic nerve function , undergo surgical implantation procedure receive NeuRx Diaphragm Pacing System device . Participants successfully implanted device use daily diaphragm condition session . Participants follow least two year ( last enrol participant reach 2-year follow-up visit ) . Safety probable benefit outcome measure assess .</brief_summary>
	<brief_title>Humanitarian Device Exemption Post-Approval Study NeuRx Diaphragm Pacing System Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This prospective , non-randomized , open-label , interventional , post-approval ( FDA ) study NeuRx Diaphragm Pacing System ( DPS ) device . The study enroll 60 participant amyotrophic lateral sclerosis ( ALS ) , meet FDA-approved device indication use , undergo surgical implantation procedure receive device . The device intend use ALS patient stimulatable diaphragm ( right leave portion ) demonstrate voluntary contraction phrenic nerve conduction study , experience chronic hypoventilation ( CH ) , progress FVC le 45 % predict . Participants successfully implanted device use daily diaphragm condition session . Participants follow least two year ( last enrol participant reach 2-year follow-up visit ) . Safety probable benefit outcome measure assess . The primary objective study : ( 1 ) ( Safety ) Characterize type frequency major device-related adverse event ( AEs ) time device use . Secondary objective study : ( 2 ) ( Safety ) Determine whether frequency major device-related AEs increase dramatically toward end life ; ( 3 ) ( Probable Benefit ) Determine whether relationship survival time onset type ( bulbar limb ) , time onset treatment , use NIV , riluzole , PEG patient treat device .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>1 . Age 21 old . 2 . Participants familial sporadic ALS diagnose laboratorysupported probable , probable , definite accord World Federation Neurology El Escorial criterion . 3 . Bilateral phrenic nerve function clinically acceptable demonstrated bilateral diaphragm movement fluoroscopic sniff test EMG recording nerve conduction time . 4 . Chronic hypoventilation document least one following : FVC le 50 % predict , |MIP| le 60 cmH2O , PaCO2 great equal 45 mmHg , Nocturnal SaO2 less equal 88 % least five continuous minute 5 . Suitable surgical candidate . 6 . Negative pregnancy test female participant childbearing potential . 7 . Informed consent patient designate representative . 1 . Underlying cardiac pulmonary disease would increase risk general anesthesia . 2 . Underlying pulmonary disease present prior ALS would affect pulmonary test independent ALS . 3 . Uncontrolled excessive secretion . 4 . FVC le 45 % predict time surgery . 5 . Preexisting implanted electrical device pacemaker cardiac defibrillator . 6 . Preexisting diaphragm abnormality hiatal hernia paraesophageal hernia abdominal content go thoracic cavity .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>motor neuron disease</keyword>
	<keyword>diaphragm</keyword>
	<keyword>diaphragm pacing</keyword>
	<keyword>diaphragmatic pacing</keyword>
	<keyword>phrenic pacing</keyword>
	<keyword>phrenic nerve</keyword>
	<keyword>phrenic nerve stimulation</keyword>
	<keyword>NeuRx DPS</keyword>
	<keyword>DPS</keyword>
	<keyword>chronic hypoventilation</keyword>
	<keyword>respiration</keyword>
	<keyword>ventilation</keyword>
	<keyword>breathing</keyword>
	<keyword>Humanitarian Device Exemption</keyword>
	<keyword>HDE</keyword>
	<keyword>post-approval study</keyword>
</DOC>